70817-26-4

Basic information

• Product Name: (1-Phenyl-1H-pyrazol-4-yl)methanol
• Synonyms: 1H-pyrazole-4-methanol, 1-phenyl-;(1-Phenyl-1H-pyrazol-4-yl)methanol;(1-phenyl-1H-pyrazol-4-yl)methanol(SALTDATA: FREE);(1-phenyl-4-pyrazolyl)methanol;(1-phenylpyrazol-4-yl)methanol;AG-613/31140002;ZINC00340724
• CAS NO: 70817-26-4
• Molecular Formula: C₁₀H₁₀N₂O
• Molecular Weight: 174.2
• Mol File: 70817-26-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 110-111 °C(Solv: water (7732-18-5))
• Boiling Point: 332.3 °C at 760 mmHg
• Flash Point: 154.8 °C
• Appearance: /
• Density: 1.16 g/cm³
• Vapor Pressure: 5.86E-05mmHg at 25°C
• Refractive Index: 1.604
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.01±0.10(Predicted)
• CAS DataBase Reference: (1-Phenyl-1H-pyrazol-4-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1-Phenyl-1H-pyrazol-4-yl)methanol(70817-26-4)
• EPA Substance Registry System: (1-Phenyl-1H-pyrazol-4-yl)methanol(70817-26-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 70817-26-4(Hazardous Substances Data)

Usage

General Description

(1-Phenyl-1H-pyrazol-4-yl)methanol, also known as 4-Hydroxy-1-[3-(phenyl)pyrazol-1-yl]benzene, is a chemical compound with the formula C13H11N3O. It is a white to off-white crystalline powder that is insoluble in water but soluble in organic solvents. (1-Phenyl-1H-pyrazol-4-yl)methanol is commonly used in the pharmaceutical and chemical industries as an intermediate for the synthesis of various bioactive compounds, including pharmaceutical drugs. It is also known to exhibit biological activities, such as anti-inflammatory and analgesic properties, making it a potential candidate for drug development. Additionally, (1-Phenyl-1H-pyrazol-4-yl)methanol is widely utilized in organic synthesis and chemical research due to its versatile reactivity and functional groups.

InChI:InChI=1/C10H10N2O/c13-8-9-6-11-12(7-9)10-4-2-1-3-5-10/h1-7,13H,8H2

Upstream product

• 54605-72-0 1-phenyl-1H-pyrazole-4-carbaldehyde 
• 1134-50-5 4-carboxy-1-phenylpyrazole 
• 885-94-9 ethyl 1-phenylpyrazole-4-carboxylate 
• 100-63-0 phenylhydrazine 
• 1126-00-7 1-phenylpyrazole 
• 107-19-7 propargyl alcohol 
• 508191-77-3 3-phenylsydnone 
• 7188-96-7 1-Phenylpyrazol-4-carbonsaeure-methylester 
• 59-88-1 phenylhydrazine hydrochloride 
• 591-50-4 iodobenzene 

Downstream Products

• 101893-32-7 1,1'-phenyl-4,4'-dipyrazolylmethane 
• 51412-23-8 (1-phenyl-1H-pyrazol-4-yl)-acetonitrile 
• 35715-77-6 (1-phenyl-1H-pyrazol-4-yl)-acetic acid 
• 35715-71-0 1-phenyl-4-pyrazolylmethyl chloride 
• 1195983-01-7 (R)-3-(1-phenylcycloheptanecarbonyloxy)-1-(1-phenyl-1H-pyrazol-4-ylmethyl)-1-azoniabicyclo[2.2.2]octane chloride 
• 1195983-13-1 (R)-1-(1-phenyl-1H-pyrazol-4-ylmethyl)-3-(1-thiophen-2-ylcycloheptanecarbonyloxy)-1-azoniabicyclo[2.2.2]octane chloride 
• 54605-72-0 1-phenyl-1H-pyrazole-4-carbaldehyde 

Relevant articles and documents

NOVEL COMPOUND AS MTOR INHIBITOR AND USE THEREOF

The present invention relates to a novel compound as an mTOR inhibitor and a use thereof and, more specifically, to a novel compound represented by formula 1 that exhibits mTOR inhibitory activity and a pharmaceutical composition comprising same as an act

Anti-inflammatory and antinociceptive activity profile of a new lead compound – LQFM219

LQFM219 is a molecule designed from celecoxibe (COX-2 inhibitor) and darbufelone (inhibitor of COX-2 and 5-LOX) lead compounds through a molecular hybridisation strategy. Therefore, this work aimed to investigate the antinociceptive and anti-inflammatory activities of this new hybrid compound. The acute oral systemic toxicity of LQFM219 was evaluated via the neutral red uptake assay. Acetic acid-induced abdominal writhing and CFA-induced mechanical hyperalgesia were performed to evaluate the antinociceptive activity, and the anti-oedematogenic activity was studied by CFA-induced paw oedema and croton oil-induced ear oedema. Moreover, the acute anti-inflammatory activity was determined by carrageenan-induced pleurisy. In addition, cell migration, myeloperoxidase enzyme activity, and TNF-α and IL-1β levels were determined in pleural exudate. Moreover, a redox assay was conducted using electroanalytical and DPPH methods. The results demonstrated that LQFM219 was classified as GHS category 4, and it showed better free radical scavenger activity compared to BHT. Besides, LQFM219 decreased the number of writhings induced by acetic acid and the response to the mechanical stimulus in the CFA-induced mechanical hyperalgesia test. Furthermore, LQFM219 reduced oedema formation, cell migration, and IL-1β and TNF-α levels in the pleural cavity and inhibited myeloperoxidase enzyme activity. Thus, our study provides that the new pyrazole derivative, LQFM219, demonstrated low toxicity, antinociceptive and anti-inflammatory potential in vitro and in vivo.

Cu-catalysed pyrazole synthesis in continuous flow

The synthesis of 1,4-disubstituted pyrazoles via the cycloaddition reaction of sydnones and terminal alkynes has been achieved employing silica-supported copper catalysts. Furthermore, this methodology has been successfully implemented in continuous flow